14 results on '"Véricel E"'
Search Results
2. Functional fluxolipidomics of polyunsaturated fatty acids and oxygenated metabolites in the blood vessel compartment
- Author
-
Lagarde, M., primary, Calzada, C., additional, Jouvène, C., additional, Bernoud-Hubac, N., additional, Létisse, M., additional, Guichardant, M., additional, and Véricel, E., additional
- Published
- 2015
- Full Text
- View/download PDF
3. Glycoxidized HDL or HDL enriched with oxidized phospholipids inhibit human platelet aggregation
- Author
-
Le, Q.H., primary, Véricel, E., additional, Lagarde, M., additional, Moulin, P., additional, and Calzada, C., additional
- Published
- 2015
- Full Text
- View/download PDF
4. Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain
- Author
-
Lagarde, M., primary, Hachem, M., additional, Bernoud-Hubac, N., additional, Picq, M., additional, Véricel, E., additional, and Guichardant, M., additional
- Published
- 2015
- Full Text
- View/download PDF
5. Biological relevance of double lipoxygenase products of polyunsaturated fatty acids, especially within blood vessels and brain.
- Author
-
Guichardant M, Véricel E, and Lagarde M
- Subjects
- Humans, Blood Vessels metabolism, Brain metabolism, Docosahexaenoic Acids metabolism, Lipoxygenases metabolism, alpha-Linolenic Acid metabolism
- Abstract
The double lipoxygenation of polyunsaturated fatty acids (PUFA) is possible with PUFA having at least three methylene-interrupted double bonds. Several PUFA of the omega-3/n-3 and -6 families may be converted through this route, and the products show interesting inhibitory effects on blood platelet function and cyclooxygenase activities. This review focuses on two main omega-3 PUFA of nutritional interest, namely docosahexaenoic acid (DHA/22:6n-3) and alpha linolenic acid (ALA/18:3n-3). The chemical configuration of the double lipoxygenase end-product from DHA (protectin DX) is compared with that of protectin D1 which is produced through a mono-lipoxygenation step followed by an epoxidation and epoxide hydrolysis process. The different metabolic pathways are discussed as well as the different biological activities of both protectins., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF
6. In vitro and in vivo bimodal effects of docosahexaenoic acid supplements on redox status and platelet function.
- Author
-
Lagarde M, Calzada C, Guichardant M, and Véricel E
- Abstract
Docosahexaenoic acid (DHA) is a prominent nutrient of marine lipids. Together with eicosapentaenoic acid, it is recognized as a protective molecule against atherosclerosis and thrombosis through the regulation of blood cell functions, especially platelets. Its high unsaturation index may however make it prone to peroxidation, which is usually considered as deleterious. This short review takes into consideration this possibility related to DHA concentrations both in vitro and in vivo. It is suggested that protective effects of DHA on platelet activation depend on the reduction of oxidative stress, and appear bimodal with the abolishment of such a protection when DHA is used at relatively high concentrations., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
7. Oxygenation of polyunsaturated fatty acids and oxidative stress within blood platelets.
- Author
-
Lagarde M, Guichardant M, Bernoud-Hubac N, Calzada C, and Véricel E
- Subjects
- Animals, Arachidonate 12-Lipoxygenase genetics, Arachidonate 12-Lipoxygenase metabolism, Blood Platelets cytology, Cyclooxygenase 1 genetics, Cyclooxygenase 1 metabolism, Fatty Acids, Unsaturated genetics, Humans, Oxidation-Reduction, Blood Platelets metabolism, Fatty Acids, Unsaturated metabolism, Oxidative Stress physiology
- Abstract
The oxygenation metabolism of arachidonic acid (ArA) has been early described in blood platelets, in particular with its conversion into the potent labile thromboxane A
2 that induces platelet aggregation and vascular smooth muscle cells contraction. In addition, the primary prostaglandins D2 and E2 have been mainly reported as inhibitors of platelet function. The platelet 12-lipoxygenase (12-LOX) product, i.e. the hydroperoxide 12-HpETE, appears to stimulate platelet ArA metabolism at the level of its release from membrane phospholipids through phospholipase A2 (cPLA2 ) and cyclooxygenase (COX-1) activities, the first enzymes in prostanoid production cascade. Also, 12-HpETE may regulate the oxygenation of other polyunsaturated fatty acids (PUFA) by platelets, especially that of eicosapentaenoic acid (EPA). On the other hand, the reduced product of 12-HpETE, 12-HETE, is able to antagonize TxA2 action. This is even more obvious for the 12-LOX end-products from docosahexaenoic acid (DHA), 11- and 14-HDoHE. In addition, 12-HpETE plays a key role in platelet oxidative stress as observed in pathophysiological conditions, but may be regulated by DHA with a bimodal way according to its concentration. Other oxygenated products of PUFA, especially omega-3 PUFA, produced outside platelets may affect platelet functions as well., (Copyright © 2018. Published by Elsevier B.V.)- Published
- 2018
- Full Text
- View/download PDF
8. Moderate intake of docosahexaenoic acid raises plasma and platelet vitamin E levels in cystic fibrosis patients.
- Author
-
Véricel E, Mazur S, Colas R, Delaup V, Calzada C, Reix P, Durieu I, Lagarde M, and Bellon G
- Subjects
- Adolescent, Adult, Child, Cross-Over Studies, Docosahexaenoic Acids pharmacology, Double-Blind Method, Drug Administration Schedule, Humans, Lipid Peroxidation, Male, Oxidative Stress genetics, Young Adult, Blood Platelets metabolism, Cystic Fibrosis blood, Docosahexaenoic Acids administration & dosage, Vitamin E blood
- Abstract
Patients with cystic fibrosis have increased oxidative stress and impaired antioxidant systems. Moderate intake of docosahexaenoic acid (DHA) may favor the lowering of oxidative stress. In this randomized, double-blind, cross-over study, DHA or placebo capsules, were given daily to 10 patients, 5mg/kg for 2 weeks then 10mg/kg DHA for the next 2 weeks (or placebo). After 9 weeks of wash-out, patients took placebo or DHA capsules. Biomarkers of lipid peroxidation and vitamin E were measured at baseline, and after 2 and 4 weeks of treatment in each phase. The proportions of DHA increased both in plasma and platelet lipids after DHA supplementations. The lipid peroxidation markers did not significantly decrease, in spite of a trend, after the first and/or the second dose of DHA but plasma and platelet vitamin E amounts increased significantly after DHA supplementation. Our findings reinforce the antioxidant potential of moderate DHA intake in subjects displaying increased oxidative stress., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. In vitro and in vivo bimodal effects of docosahexaenoic acid supplements on redox status and platelet function.
- Author
-
Lagarde M, Calzada C, Guichardant M, and Véricel E
- Abstract
Docosahexaenoic acid (DHA) is a prominent nutrient of marine lipids. Together with eicosapentaenoic acid, it is recognized as a protective molecule against atherosclerosis and thrombosis through the regulation of blood cell functions, especially platelets. Its high unsaturation index may however make it prone to peroxidation, which is usually considered as deleterious. This short review takes into consideration this possibility related to DHA concentrations both in vitro and in vivo. It is suggested that protective effects of DHA on platelet activation depend on the reduction of oxidative stress, and appear bimodal with the abolishment of such a protection when DHA is used at relatively high concentrations., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. Glutathione peroxidase 4 is reversibly induced by HCV to control lipid peroxidation and to increase virion infectivity.
- Author
-
Brault C, Lévy P, Duponchel S, Michelet M, Sallé A, Pécheur EI, Plissonnier ML, Parent R, Véricel E, Ivanov AV, Demir M, Steffen HM, Odenthal M, Zoulim F, and Bartosch B
- Subjects
- Adult, Biomarkers, Biopsy, Case-Control Studies, Cell Line, Female, Gas Chromatography-Mass Spectrometry, Hepacivirus metabolism, Hepatitis C, Chronic enzymology, Hepatitis C, Chronic pathology, Humans, Liver enzymology, Liver pathology, Male, Middle Aged, Oxidative Stress, Phospholipid Hydroperoxide Glutathione Peroxidase, Reactive Oxygen Species metabolism, Virion metabolism, Glutathione Peroxidase metabolism, Hepacivirus pathogenicity, Hepatitis C, Chronic virology, Lipid Peroxidation, Liver virology, Virion pathogenicity
- Abstract
Objective: Inflammation and oxidative stress drive disease progression in chronic hepatitis C (CHC) towards hepatocellular carcinoma. HCV is known to increase intracellular levels of reactive oxygen species (ROS), but how it eliminates ROS is less well known. The role of the ROS scavenger glutathione peroxidase 4 (GPx4), induced by HCV, in the viral life cycle was analysed., Design: The study was performed using a replicative in vitro HCV infection model and liver biopsies derived from two different CHC patient cohorts., Results: A screen for HCV-induced peroxide scavengers identified GPx4 as a host factor required for HCV infection. The physiological role of GPx4 is the elimination of lipid peroxides from membranes or lipoproteins. GPx4-silencing reduced the specific infectivity of HCV by up to 10-fold. Loss of infectivity correlated with 70% reduced fusogenic activity of virions in liposome fusion assays. NS5A was identified as the protein that mediates GPx4 induction in a phosphatidylinositol-3-kinase-dependent manner. Levels of GPx4 mRNA were found increased in vitro and in CHC compared with control liver biopsies. Upon successful viral eradication, GPx4 transcript levels returned to baseline in vitro and also in the liver of patients., Conclusions: HCV induces oxidative stress but controls it tightly by inducing ROS scavengers. Among these, GPx4 plays an essential role in the HCV life cycle. Modulating oxidative stress in CHC by specifically targeting GPx4 may lower specific infectivity of virions and prevent hepatocarcinogenesis, especially in patients who remain difficult to be treated in the new era of interferon-free regimens., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
11. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients.
- Author
-
Véricel E, Colas R, Calzada C, Lê QH, Feugier N, Cugnet C, Vidal H, Laville M, Moulin P, and Lagarde M
- Subjects
- Administration, Oral, Antioxidants pharmacology, Arachidonic Acid metabolism, Blood Platelets chemistry, Collagen pharmacology, Cross-Over Studies, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 urine, Dinoprost analogs & derivatives, Dinoprost blood, Docosahexaenoic Acids pharmacology, Dose-Response Relationship, Drug, Double-Blind Method, F2-Isoprostanes urine, Fatty Acids blood, Female, Humans, Lipid Peroxidation drug effects, Membrane Lipids blood, Middle Aged, Phospholipids blood, Platelet Aggregation drug effects, Postmenopause, Thromboxane B2 analogs & derivatives, Thromboxane B2 blood, Thromboxane B2 urine, alpha-Tocopherol blood, Antioxidants therapeutic use, Blood Platelets drug effects, Diabetes Mellitus, Type 2 drug therapy, Dietary Supplements, Docosahexaenoic Acids therapeutic use, Lipids blood, Oxidative Stress drug effects
- Abstract
Platelets from patients with type 2 diabetes are characterised by hyperactivation and high level of oxidative stress. Docosahexaenoic acid (DHA) may have beneficial effects on platelet reactivity and redox status. We investigated whether moderate DHA supplementation, given as a triglyceride form, may correct platelet dysfunction and redox imbalance in patients with type 2 diabetes. We conducted a randomised, double-blind, placebo-controlled, two-period crossover trial (n=11 post-menopausal women with type 2 diabetes) to test the effects of 400 mg/day of DHA intake for two weeks on platelet aggregation, markers of arachidonic acid metabolism, lipid peroxidation status, and lipid composition. Each two week-period was separated from the other by a six-week washout. Daily moderate dose DHA supplementation resulted in reduced platelet aggregation induced by collagen (-46.5 %, p< 0.001), and decreased platelet thromboxane B2 (-35 %, p< 0.001), urinary 11-dehydro-thromboxane B2 (-13.2 %, p< 0.001) and F2-isoprostane levels (-19.6 %, p< 0.001) associated with a significant increase of plasma and platelet vitamin E concentrations (+20 % and +11.8 %, respectively, p< 0.001). The proportions of DHA increased both in plasma lipids and in platelet phospholipids. After placebo treatment, there was no effect on any parameters tested. Our findings support a significant beneficial effect of low intake of DHA on platelet function and a favourable role in reducing oxidative stress associated with diabetes.
- Published
- 2015
- Full Text
- View/download PDF
12. Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.
- Author
-
Lê QH, El Alaoui M, Véricel E, Ségrestin B, Soulère L, Guichardant M, Lagarde M, Moulin P, and Calzada C
- Subjects
- Adult, Aged, Blood Platelets metabolism, Calcium metabolism, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Signal Transduction drug effects, Young Adult, p38 Mitogen-Activated Protein Kinases metabolism, Blood Platelets drug effects, Diabetes Mellitus, Type 2 metabolism, Lipoproteins, HDL pharmacology, Phospholipids pharmacology, Platelet Activation drug effects, Platelet Aggregation drug effects
- Abstract
Context: High-density lipoproteins (HDL) possess atheroprotective properties including anti-thrombotic and antioxidant effects. Very few studies relate to the functional effects of oxidized HDL on platelets in type 2 diabetes (T2D)., Objective: The objective of our study was to investigate the effects of in vitro glycoxidized HDL and HDL from patients with T2D on platelet aggregation and arachidonic acid signaling cascade. At the same time, the contents of hydroxylated fatty acids were assessed in HDL., Results: Compared with control HDL, in vitro glycoxidized HDL had decreased proportions of linoleic (LA) and arachidonic (AA) acids in phospholipids and cholesteryl esters, and increased concentrations of hydroxy-octadecadienoic acids (9-HODE and 13-HODE) and 15-hydroxy-eicosatetraenoic acid (15-HETE), derived from LA and AA respectively, especially hydroxy derivatives esterified in phospholipids. Glycoxidized HDL dose-dependently decreased collagen-induced platelet aggregation by binding to scavenger receptor BI (SR-BI). Glycoxidized HDL prevented collagen-induced increased phosphorylation of platelet p38 MAPK and cytosolic phospholipase A2, as well as intracellular calcium mobilization. HDL enriched with oxidized phosphatidylcholine (PC), namely PC(16:0/13-HODE) dose-dependently inhibited platelet aggregation. Increased concentrations of 9-HODE, 13-HODE, and 15-HETE in phospholipids (2.1-, 2.1-, and 2.4-fold increase, respectively) were found in HDL from patients with T2D, and these HDL also inhibited platelet aggregation via SR-BI., Conclusions: Our results suggest that in vitro glycoxidized HDL as well as HDL from patients with T2D inhibit platelet aggregation, and suggest that oxidized LA-containing phospholipids may contribute to the anti-aggregatory effects of glycoxidized HDL and HDL from patients with T2D.
- Published
- 2015
- Full Text
- View/download PDF
13. Omega-3 polyunsaturated fatty acids and oxygenated metabolism in atherothrombosis.
- Author
-
Guichardant M, Calzada C, Bernoud-Hubac N, Lagarde M, and Véricel E
- Subjects
- Animals, Atherosclerosis epidemiology, Atherosclerosis metabolism, Cardiovascular Agents adverse effects, Cardiovascular Agents metabolism, Docosahexaenoic Acids therapeutic use, Dose-Response Relationship, Drug, Eicosapentaenoic Acid therapeutic use, Fatty Acids, Omega-3 adverse effects, Fatty Acids, Omega-3 metabolism, Humans, Oxidation-Reduction, Risk Assessment, Risk Factors, Thrombosis epidemiology, Thrombosis metabolism, Treatment Outcome, alpha-Linolenic Acid therapeutic use, Atherosclerosis drug therapy, Cardiovascular Agents therapeutic use, Fatty Acids, Omega-3 therapeutic use, Thrombosis drug therapy
- Abstract
Numerous epidemiological studies and clinical trials have reported the health benefits of omega-3 polyunsaturated fatty acids (PUFA), including a lower risk of coronary heart diseases. This review mainly focuses on the effects of alpha-linolenic (ALA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on some risk factors associated with atherothrombosis, including platelet activation, plasma lipid concentrations and oxidative modification of low-density lipoproteins (LDL). Special focus is given to the effects of marine PUFA on the formation of eicosanoids and docosanoids, and to the bioactive properties of some oxygenated metabolites of omega-3 PUFA produced by cyclooxygenases and lipoxygenases. The antioxidant effects of marine omega-3 PUFA at low concentrations and the pro-oxidant effects of DHA at high concentrations on the redox status of platelets and LDL are highlighted. Non enzymatic peroxidation end-products deriving from omega-3 PUFA such as hydroxy-hexenals, neuroketals and EPA-derived isoprostanes are also considered in relation to atherosclerosis. This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance"., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
14. Structure-function relationships of non-cyclic dioxygenase products from polyunsaturated fatty acids: poxytrins as a class of bioactive derivatives.
- Author
-
Lagarde M, Véricel E, Liu M, Chen P, and Guichardant M
- Subjects
- Dioxygenases metabolism, Docosahexaenoic Acids metabolism, Docosahexaenoic Acids pharmacology, Fatty Acids, Omega-3 metabolism, Fatty Acids, Unsaturated metabolism, Humans, Molecular Structure, Platelet Aggregation drug effects, Stereoisomerism, Structure-Activity Relationship, alpha-Linolenic Acid metabolism, alpha-Linolenic Acid pharmacology, Docosahexaenoic Acids chemistry, Fatty Acids, Omega-3 chemistry, Fatty Acids, Unsaturated chemistry, alpha-Linolenic Acid chemistry
- Abstract
More and more attention is paid to omega-3 fatty acids because of their potential activities in preventing cardiovascular events. In this brief review, we focus on the lipoxygenase end-metabolites of two relevant nutrients belonging to the omega-3 family fatty acids: alpha-linolenic and docosahexaenoic acids, the latter being a prominent component of brain lipids. Dihydroxylated derivatives are described as well as their inhibitory effects on platelet aggregation and cyclooxygenase activities. We point out that only the dihydroxylated products with the trans,cis,trans/E,Z,E conjugated triene geometry exhibit those inhibitory activities. These properties being found with other polyunsaturated fatty acid oxygenated products sharing the same E,Z,E molecular motif, they have been collectively named poxytrins. From alpha-linolenic and docosahexaenoic acids, poxytrins are linotrins and protectin DX, respectively., (Copyright © 2014 Elsevier B.V. and Société française de biochimie et biologie Moléculaire (SFBBM). All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.